Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Optimer Pharmaceuticals, Inc.
Holzer Holzer & Fistel, LLC is investigating potential shareholder claims on behalf of investors who currently own Optimer Pharmaceuticals, Inc.
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Optimer Pharmaceuticals...
Former Attorney General of Louisiana Charles C. Foti, Jr.
Levi & Korsinsky is investigating the Board of Directors of Optimer Pharmaceuticals, Inc.
Milberg LLP is currently investigating the proposed acquisition of Optimer Pharmaceuticals, Inc.
Rigrodsky & Long, P.A.
Cubist Pharmaceuticals on Tuesday committed up to $1.6 billion to acquire two makers of next-generation antibiotics in a bid to expand aggressively its acute care product portfolio.
The law firm of Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Optimer Pharmaceuticals, Inc.
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor, LLP are investigating the sale of Optimer Pharmaceuticals, Inc.
Shareholder Rights Law Firm Johnson & Weaver, LLP is investigating whether members of the board of directors of Optimer Pharmaceuticals, Inc.
Stock futures are little changed Wednesday despite upbeat reports on GDP and jobs ahead of the Fed announcement.
U.S. stock futures suggest a flat to slightly higher start for Wall Street; Cubist Pharmaceuticals makes two acquisitions; MasterCard and Comcast highlight the earnings calendar.
The law firm of Wohl & Fruchter LLP is investigating the proposed acquisition of Optimer Pharmaceuticals, Inc.
Levi & Korsinsky is investigating the Board of Directors of Optimer Pharmaceuticals, Inc.
Cubist announces two acquisitions in one day.
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) and Optimer Pharmaceuticals, Inc.
These stocks look ready to break out and trade higher from current levels.
Investors eyeing a purchase of Optimer Pharmaceuticals Inc shares, but tentative about paying the going market price of $14.16/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the July put at the $10 strike, which has a bid at the time of this writing of 30 cents.
The pace of deals among developers of antibiotics is about to ramp higher.
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.
Once a stock trends to a new high, or takes out a prior overhead resistance point, then it's free to find new buyers and momentum players that can ultimately push the stock significantly higher.
The fourth quarter earnings season has just begun. Some companies manage to consistently surprise the market with positive earnings reports. [...]
Here are several biotech and pharma stocks under $10 that are making large moves to the upside today.
Often when above average volume moves into equity, it precedes a large spike in volatility.
Optimer Pharmaceuticals Management Discusses Q2 2012 Results - Earnings Call Transcript
Optimer Pharmaceuticals (Nasdaq:OPTR) has been downgraded by TheStreet Ratings from from a hold to sell.
